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MaBACKGROUND Few studies have evaluated out-of-ofﬁce blood pressure (BP) measurements as predictors of coronary
artery disease (CAD) events.
OBJECTIVES The aim of this study was to determine morning home blood pressure (HBP) as a predictor of CAD events.
METHODS Using data from the HONEST (Home blood pressure measurement with Olmesartan Naive patients to
Establish Standard Target blood pressure) study, we investigated the relationship between morning HBP and incidence of
stroke and CAD events.
RESULTS In 21,591 treated hypertensive patients (mean age 64.9 years; mean follow-up 2.02 years), 127 stroke
events (2.92 per 1,000 patient-years), and 121 CAD events (2.78 per 1,000 patient-years) occurred. The incidence of
stroke events was signiﬁcantly higher in patients with morning home systolic blood pressure (HSBP) $145 mm Hg
compared with <125 mm Hg, and in patients with clinic systolic blood pressure (CSBP) $150 mm Hg compared with
<130 mm Hg. Hazard ratios (HRs) were 6.01 (95% conﬁdence interval [CI]: 2.85 to 12.68) between patients with morning
HSBP $155 mm Hg and those with morning HSBP <125 mm Hg and 5.82 (95% CI: 3.17 to 10.67) between patients
with CSBP $160 mm Hg and those with CSBP <130 mm Hg; morning HSBP predicted stroke events similarly to CSBP.
Incidence of CAD events was signiﬁcantly higher in patients with morning HSBP$145 mm Hg compared with<125 mm Hg
and in patients with CSBP $160 mm Hg compared with <130 mm Hg. The HR for morning HSBP $155 mm Hg was 6.24
(95%CI: 2.82 to 13.84) and for CSBP$160mmHgwas 3.51 (95%CI: 1.71 to 7.20); therefore, comparedwithmorning HSBP,
CSBP may underestimate CAD risk. Goodness-of-ﬁt analysis showed that morning HSBP predicted CAD events more
strongly than CSBP.
CONCLUSIONS Morning HBP is a strong predictor of future CAD and stroke events, and may be superior to
clinic BP in this regard. There does not appear to be a J-curve in the relationship between morning HBP and
stroke or CAD events. (Home blood pressure measurement with Olmesartan Naive patients to Establish Standard Target
blood pressure Study [HONEST]; UMIN000002567) (J Am Coll Cardiol 2016;67:1519–27)
© 2016 by the American College of Cardiology Foundation.m the aDivision of Cardiology, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan; bKeio
iversity, Kanagawa, Japan; cThe Life Planning Center Foundation, Tokyo, Japan; dDepartment of Biostatistics, Graduate School
Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; eDaiichi-Sankyo Co., Ltd., Tokyo, Japan; and the
in-Oyama City Hospital, Oyama, Japan. This study was supported by funding from Daiichi-Sankyo Co., Ltd. (Tokyo, Japan).
tistical analyses were done by EPS Corporation under the direction of the sponsor and the authors. Medical editorial assistance
s provided by Nature Japan KK (Macmillan Medical Communications) and funded by Daiichi-Sankyo Co., Ltd. Drs. Kario, Saito,
shiro, Teramukai, and Shimada have received honoraria from Daiichi-Sankyo Co., Ltd. Mr. Tomono and Mr. Okuda are
ployees of Daiichi-Sankyo Co., Ltd.
nuscript received November 12, 2015; revised manuscript received January 20, 2016, accepted January 22, 2016.
ABBR EV I A T I ON S
AND ACRONYMS
ABPM = ambulatory blood
pressure monitoring
BP = blood pressure
CAD = coronary artery disease
CBP = clinic blood pressure
CSBP = clinic systolic blood
pressure
DBP = diastolic blood pressure
HBP = home blood pressure
HDBP = home diastolic blood
pressure
HR = hazard ratio
HSBP = home systolic blood
pressure
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1520M any studies have shown thatclinic blood pressure (CBP) is auseful predictor of cardiovascular
events, such as stroke and coronary artery
disease (CAD) (1–4). In some of these studies,
the relationship between CBP and stroke
events and between CBP and CAD events
was investigated separately. The results
showed that although CBP is a strong predic-
tor of stroke events, it might not be effective
in predicting CAD events (4,5).
The relationship between out-of-ofﬁce
blood pressure (BP), such as ambulatory BP
and home blood pressure (HBP), and cardio-
vascular events has been investigated in
several studies (6–16). However, there is
insufﬁcient evidence as yet regarding whichBP measurement predicts CAD events most strongly.
IDACO (International Database on Ambulatory Blood
Pressure in Relation to Cardiovascular Outcomes) was
a large-scale database study in which the relationship
between ambulatory BP and CAD events was inves-
tigated (14). Its results showed that 24-h diastolic
blood pressure (DBP) and isolated diastolic hyper-
tension predict CAD in untreated people <50 years of
age. The results of the Ohasama study (6,7) and the
Finn-HOME study (8) showed that HBP correlates
signiﬁcantly with the hazard ratio (HR) for cardiovas-
cular events, but the relationship between HBP and
CAD events was not reported. Therefore, it is unclear
which BP measurement predicts CAD events most
strongly. Among out-of-ofﬁce BP measurements, HBP
has the advantage of being easy to measure, allowing
multiple measurements and long-term monitoring.SEE PAGE 1528However, it remains unclear as to which time of day
HBP should be measured to predict CAD events effec-
tively. We have found that morning hypertension
predicts cardiovascular events because both incidence
of cardiovascular events and BP peak in the early
morning (17). In 1 of our previous studies, the results of
ambulatory blood pressure monitoring (ABPM)
showed that ambulatory morning systolic BP (the 2-h
average of systolic BP measurements recorded just
after waking) is the strongest predictor of stroke events
in elderly hypertensive patients (17). However, we
were unable to determine which BP is the strongest
predictor of CAD events because of the small number of
such events that occurred in the study period.
Therefore, we investigated the relationship be-
tween morning HBP and the incidence of CAD events
and stroke events using data from the largest
real-world prospective study, the HONEST (Homeblood pressure measurement with Olmesartan Naive
patients to Establish Standard Target blood pressure)
study (18,19). Previous analysis of the HONEST study
focused on a composite cardiovascular endpoint (19);
in contrast, the present analysis addresses the rela-
tionship between morning HBP and the separate
components of the composite cardiovascular
endpoint: CAD and stroke events.
METHODS
PATIENTS. The inclusion and exclusion criteria for
the HONEST study have already been reported (18).
Brieﬂy, olmesartan-naive outpatients with a
physician-reported diagnosis of essential hyperten-
sion, who already owned a validated and approved
electronic device for measuring HBP using the
cuff-oscillometric principle, and who had recorded
their morning HBP on 2 of the 28 days before starting
olmesartan therapy, were eligible to participate. No
BP range was speciﬁed as a criterion for eligibility.
Patients were registered after being prescribed
olmesartan in the period between October 1, 2009,
and September 30, 2010.
ETHICS COMMITTEE APPROVAL AND INFORMED
CONSENT. The ethical committee of Daiichi-Sankyo
Co., Ltd., and the research ethics committees of the
participating institutions approved the protocol of the
HONEST study, at their discretion. The study was
pre-approved by the Ministry of Health, Labour and
Welfare of Japan and complied with Japanese Phar-
maceutical Affairs Law. The study was carried out at
registered medical institutions in compliance with
Good Post-Marketing Study Practice and each in-
stitution’s internal regulations for clinical studies. All
study participants providedwritten informed consent.
STUDY DESIGN. The aim of this study was to inves-
tigate the relationship between morning HBP and
incidence of stroke events and CAD events, using data
from the HONEST study (18). It is registered at the
UMIN Clinical Trials Registry with the unique trial
number UMIN000002567.
BP TARGETS AND ANTIHYPERTENSIVE DRUG THERAPY.
BP targets and olmesartan dose (administered orally,
generally 10 or 20mg once daily) were at the discretion
of individual physicians. Regarding the use of antihy-
pertensive drugs before the study, only prior olme-
sartan therapy was an exclusion criterion. No
restrictions were placed on the use of combination
antihypertensive drug therapy during the study
period.
DATA COLLECTION. Data used in the present anal-
ysis were patient characteristics, HBP measurements,
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1521clinical laboratory test values, and incidence of
stroke, CAD, and adverse events during the study
period. An Internet-based central data-capturing
system (PostMaNet, Fujitsu FIP, Tokyo, Japan) was
used. Data obtained from participating institutions
were not cross-checked against medical records.
HBP MEASUREMENT. Patients were asked to measure
their HBP twice in the morning and twice at bedtime,
according to the guidelines of the Japanese Society of
Hypertension (20). During the follow-up period, HBP
was measured at 1, 4, and 16 weeks, and at 6, 12, 18,
and 24 months. Patients measured their HBP twice in
the morning and twice at bedtime on 2 different days
for each measurement point. The average of the 2
HBP measurements at each time was calculated. For
each measurement point, we used the average HBP
over 2 days. Average HBP measurements during
follow-up, excluding baseline values, were used in
the analysis of their relationship with incidence of
stroke and CAD events. For patients who had such
events, we used the average of HBP measurements
obtained until their ﬁrst occurrence.
CBP MEASUREMENT. CBP was measured according to
the usual methods of each institution. During the
follow-up period, CBPwasmeasured at 4 and 16weeks,
and at 6, 12, 18, and 24 months. For each measurement
point, 1 measurement was reported. Average CBP
measurements during follow-up, excluding baseline
values, were used in the analysis. For patients who had
stroke or CAD events, we used the average of CBP
measurements obtained until their ﬁrst occurrence.
EVALUATION OF STROKE AND CAD EVENTS. Event
review committees evaluated events, precisely as
described previously (18). All ischemic and hemor-
rhagic cerebrovascular events, except for transient
ischemic attacks, were deﬁned as stroke events.
Myocardial infarction and angina pectoris with coro-
nary revascularization procedure were deﬁned as
CAD events. The present analysis excluded sudden
death events, 1 of the composite cardiovascular end-
points in the previous analysis of the HONEST study
(19). Events were evaluated according to event deﬁ-
nitions by 3 separate event review committees: 1 for
stroke events; 1 for CAD events; and 1 for other
events, including other vascular and renal diseases.
Each event review committee consisted of 2 or more
specialists who identiﬁed all events according to
pre-determined event deﬁnitions. All well-validated
clinical information on each stroke and CAD event is
listed in a supplement to our previous paper (19).
STATISTICAL ANALYSIS. In the present analysis,
we used data from eligible patients who had
received olmesartan at least once. We used the Coxproportional hazards model to investigate the rela-
tionship between on-treatment HBP or CBP and inci-
dence of stroke or CAD events. We also conducted the
likelihood ratio test to assess whether the addition of
HBP and/or CBP improved the goodness-of-ﬁt of the
model for stroke or CAD events. All statistical tests
were 2-sided, and a signiﬁcance level of 0.05 was
used. SAS release 9.2 software (SAS Institute, Cary,
North Carolina) was used for all statistical analyses.
RESULTS
STUDY PROFILE. The study proﬁle of the HONEST
study has already been reported (19). Of the 22,373
patients who were registered, case report forms were
collected from 22,298, and data from 21,591 were
included in the analysis. The mean follow-up period
was 2.02  0.50 years (median and maximum
follow-up periods were 2.08 and 3.4 years, respec-
tively). Of the 21,591 patients whose data were used,
10,921 (51%) were women, and the mean age was 64.9
 11.9 years. During the follow-up period, 425 pa-
tients withdrew consent (but agreed to the use of data
obtained until then), and 190 patients died. Of the
patients who agreed to continue to participate in the
study, contact was lost with 1,950 (9.0%), and their
follow-up period was <21 months.
CHANGE IN BP. Online Figure 1 shows changes in
morning HBP and CBP during the follow-up period.
Morning HBP and CBP at baseline (systolic BP/DBP)
were 151.2  16.3/86.9  11.7 mm Hg and 153.6 
19.0/87.1  13.3 mm Hg, respectively. During
follow-up, mean morning home systolic blood pres-
sure (HSBP) and clinic systolic blood pressure (CSBP)
were 135.2  10.8/79.0  8.4 mm Hg and 135.2  11.
5/77.4  8.6 mm Hg, respectively.
INCIDENCE OF STROKE AND CAD EVENTS. Of the
21,591 patients whose data were included in the ﬁnal
analysis, the number of stroke events and CAD events
were 127 (2.92 per 1,000 patient-years) and 121 (2.78
per 1,000 patient-years), respectively, and 21,345
patients experienced neither a stroke nor a CAD
event. Subtypes of stroke and CAD events are shown
in Online Table 1. One patient had 2 stroke events
(lacunar infarction and unclassiﬁed stroke), and 1
patient had 2 CAD events (myocardial infarction and
angina pectoris). Two patients developed both stroke
and CAD events. In the analysis of stroke or CAD, we
used the ﬁrst occurrence as an event. Table 1 shows
the baseline characteristics of patients with stroke
events, CAD events, and no events. The prevalence of
diabetes mellitus and chronic kidney disease in pa-
tients with stroke events and of dyslipidemia, dia-
betes mellitus, chronic kidney disease, and cardiac
TABLE 1 Baseline Characteristics of Patients With No Events, Stroke Events,
or CAD Events
No Events
(n ¼ 21,345)
Stroke Events
(n ¼ 127)
CAD Events
(n ¼ 121)
Women 10,840 (51) 52 (41)* 30 (25)†
Age, yrs 64.8  11.9 69.6  11.2† 69.6  10.5†
Body mass index, kg/m2 24.3  3.7 23.6  3.5 23.4  2.8*
Disease history
Cerebrovascular disease or CAD 2,192 (10) 39 (31)† 38 (31)†
Cerebrovascular disease 1,389 (7) 31 (24)† 12 (10)
CAD 939 (4) 11 (9)* 31 (26)†
Complications
Dyslipidemia 9,489 (45) 55 (43) 83 (69)†
Diabetes mellitus 4,335 (20) 36 (28)* 56 (46)†
Chronic kidney disease 4,273 (20) 37 (29)‡ 37 (31)‡
Cardiac disease 1,967 (9) 17 (13) 35 (29)†
Current smokers 2,615 (12) 18 (14) 21 (17)†
Regular alcohol drinkers 3,428 (16) 20 (16) 25 (21)
Previously used antihypertensive drugs 10,717 (50) 74 (58) 82 (68)†
Calcium-channel blocker 7,670 (36) 56 (44) 58 (48)‡
Angiotensin II receptor blocker 4,526 (21) 20 (16) 35 (29)*
Beta-blocker 1,349 (6) 12 (9) 19 (16)†
Diuretic agent 1,239 (6) 9 (7) 12 (10)
Angiotensin-converting
enzyme inhibitor
772 (4) 4 (3) 9 (7)*
Alpha-blocker 465 (2) 2 (2) 3 (3)
Other 97 (1) 0 (0) 0 (0)
Drugs used at study entry
Lipid-lowering drugs 6,045 (28) 31 (24) 51 (42)†
Antidiabetic drugs 2,928 (14) 21 (17) 37 (31)†
Anticoagulant or antiplatelet drugs 2,610 (12) 35 (28)† 40 (33)†
Lipid proﬁle
Total cholesterol, mg/dl 202.6  35.9 191.2  35.6* 193.0  40.0*
Low-density lipoprotein
cholesterol, mg/dl
118.8  30.9 113.1  32.4 109.6  32.4‡
High-density lipoprotein
cholesterol, mg/dl
58.5  15.7 57.0  15.2 53.8  15.9‡
Triglycerides, mg/dl 133.0  84.3 132.6  70.7 177.6  251.5†
Fasting plasma glucose, mg/dl 105.9  29.6 114.3  36.1 118.8  45.8‡
HbA1c (NGSP), % 6.18  1.09 6.55  1.31‡ 6.68  1.28†
Creatinine, mg/dl 0.79  0.31 0.88  0.46‡ 0.91  0.45†
Estimated glomerular ﬁltration
rate, ml/min/1.73 m2
72.4  20.2 70.4  22.1 66.6  18.9‡
Values are n (%) or mean  SD. *p < 0.05, †p < 0.001, and ‡p < 0.01 vs. no events group.
CAD ¼ coronary artery disease; HbA1c ¼ glycosylated hemoglobin; NGSP ¼ National Glycohemoglobin Stan-
dardization Program.
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1522disease in patients with CAD events was higher than
in patients with no events.
RELATIONSHIP BETWEEN BP AND STROKE OR CAD
EVENTS DURING FOLLOW-UP. We investigated the
incidence and HR of stroke and CAD events in 5 cat-
egories of morning HSBP and CSBP in relation to
morning HSBP <125 mm Hg or CSBP <130 mm Hg.
The incidence and HR of stroke and CAD events in
each category are shown in Figure 1 and the Central
Illustration, respectively. The incidence of strokeevents was signiﬁcantly higher in patients with
morning HSBP 145 to <155 mm Hg (3.97 per 1,000
patient-years) or $155 mm Hg (12.57 per 1,000 patient-
years) than in those with morning HSBP <125 mm Hg
(Figure 1A), and in patients with CSBP 150 to <160
mm Hg (4.88 per 1,000 patient-years) or $160 mm Hg
(14.17 per 1,000 patient-years) compared with <130
mm Hg (Figure 1B).
The HR for stroke events was signiﬁcantly higher in
patients with morning HSBP $155 mm Hg than in
those with morning HSBP <125 mm Hg (HR: 6.01;
95% conﬁdence interval [CI]: 2.85 to 12.68), and it
tended to increase in patients with morning HSBP
from 145 to <155 mm Hg compared with <125 mm Hg
(HR: 1.90; 95% CI: 0.90 to 3.99; p ¼ 0.091) (Central
Illustration, panel A). The HRs for stroke events
were signiﬁcantly higher in patients with CSBP from
150 to <160 mm Hg (HR: 2.00; 95% CI: 1.06 to 3.76)
or $160 mm Hg (HR: 5.82; 95% CI: 3.17 to 10.67) than
in those with CSBP <130 mm Hg (Central Illustration,
panel B). The incidence and HR of stroke events were
signiﬁcantly higher in patients with evening HSBP
>145 mm Hg (Online Figures 2 and 3). These results
showed that morning and evening HSBP predicted
stroke events similarly to CSBP.
The incidence of CAD events was signiﬁcantly
higher in patients with morning HSBP 145 to
<155 mm Hg (4.15 per 1,000 patient-years) or $155
mm Hg (12.61 per 1,000 patient-years) than in those
with morning HSBP <125 mm Hg (Figure 1C), and in
patients with CSBP $160 mm Hg compared with <130
mm Hg (8.82 per 1,000 patient-years) (Figure 1D). The
HR for CAD events was signiﬁcantly higher in patients
with morning HSBP $155 mm Hg than in those with
morning HSBP <125 mm Hg (HR: 6.24; 95% CI: 2.82 to
13.84), and it tended to increase in patients with
morning HSBP 145 to <155 mm Hg compared with
<125 mm Hg (HR: 2.15; 95% CI: 0.98 to 4.71; p ¼ 0.056).
In contrast, the HR for CAD was signiﬁcantly higher
only in patients with CSBP $160 mm Hg (HR: 3.51;
95% CI: 1.71 to 7.20). We also conducted Cox regres-
sion analysis using BP as a time-varying covariate;
similar results were observed (Online Table 2).
As for evening HSBP, the incidence and HR of CAD
events were signiﬁcantly higher in patients with
evening HSBP >155 mm Hg but not in those with
evening HSBP from 145 to <155 mm Hg (Online
Figures 2 and 3). These results showed that,
compared with morning HSBP, CSBP and evening SBP
may underestimate CAD risk.
There does not appear to be a J-curve phenomenon
in the relationship between morning HBP and stroke
or CAD events (Central Illustration). To further inves-
tigate the J-curve relationship, we subdivided the
FIGURE 1 SBP and Incidence Rate of Stroke and CAD Events During Follow-Up
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Relationship between mean morning HSBP (A) and CSBP (B) and incidence rate of stroke events, and between morning HSBP (C) and CSBP (D) and incidence
rate of CAD events. *p < 0.05, †p < 0.01, and ‡p < 0.001 versus morning HSBP <125 mm Hg (A and C) or CSBP <130 mm Hg (B and D). CAD ¼ coronary
artery disease; CSBP ¼ clinic systolic blood pressure; HSBP ¼ home systolic blood pressure; SBP ¼ systolic blood pressure.
J A C C V O L . 6 7 , N O . 1 3 , 2 0 1 6 Kario et al.
A P R I L 5 , 2 0 1 6 : 1 5 1 9 – 2 7 Morning Home BP and Coronary Artery Disease
1523category of morning HSBP <125 mm Hg into <115
mm Hg and 115 to <125 mm Hg. The number of stroke
events or CAD events per total number of patients
(incidence rate) was 0 of 417 patients or 2 of 416 pa-
tients (2.49 per 1,000 patient-years) at morning
HSBP <115 mm Hg, and 11 of 2,590 patients (2.06 per
1,000 patient-years) or 7 of 2,594 patients (1.31 per
1,000 patient-years) at morning HSBP 115 to <125
mm Hg, respectively. These methods have limitations
because of the small numbers of stroke or CAD events
at morning HSBP <125 mm Hg. Therefore, we con-
ducted a spline regression analysis to investigate
relative risks of stroke and CAD events in association
with morning HSBP. As a result, relative risks of
stroke and CAD events did not increase until morning
HSBP <110 mm Hg (Online Figure 4).GOODNESS OF FIT ANALYSIS OF MORNING HBP
VERSUS CBP FOR STROKE OR CAD EVENTS. We
investigated the goodness of ﬁt of the models for
stroke or CAD events by the likelihood ratio test
(Table 2). Goodness-of-ﬁt of the model for stroke or
CAD events was improved by adding CSBP or morning
HSBP to the model including only confounders. When
morning HSBP was added to the CSBP model, the
goodness-of-ﬁt of the model for stroke or CAD events
was signiﬁcantly improved (p < 0.001 for stroke;
p < 0.001 for CAD). In contrast, when CSBP was added
to the morning HSBP model, the goodness-of-ﬁt of
the model for stroke events was signiﬁcantly, but
more weakly, improved (p < 0.05), and the
goodness-of-ﬁt of the model for CAD events was not
signiﬁcantly improved (p ¼ 0.434).
CENTRAL ILLUSTRATION Morning Home Blood Pressure and CAD: SBP and HR for Stroke and CAD Events During Follow-Up
Kario, K. et al. J Am Coll Cardiol. 2016;67(13):1519–27.
Relationship betweenmeanmorning home systolic blood pressure (SBP) (C) and clinical SBP and hazard ratio (HR) for coronary artery disease (CAD) events. The Cox
proportional hazards model was used, adjusting for sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic kidney disease, history of
cardiovasculardisease,andsmokingstatus.*p<0.05and‡p<0.001versusmorninghomeSBP<125mmHg (AandC)orclinicalSBP<130mmHg (BandD).Vertical lines
indicate 95% conﬁdence intervals.
Kario et al. J A C C V O L . 6 7 , N O . 1 3 , 2 0 1 6
Morning Home BP and Coronary Artery Disease A P R I L 5 , 2 0 1 6 : 1 5 1 9 – 2 7
1524DIASTOLIC BP. We also investigated the relationship
between DBP and stroke or CAD events (Online
Figures 5 and 6). The HR for stroke events was
signiﬁcantly higher in patients with morning home
diastolic blood pressure (HDBP) $90 mm Hg (HR:
3.59; 95% CI: 1.88 to 6.87) than in those with morn-
ing HDBP <75 mm Hg (Online Figure 6A), and in
patients with clinic DBP $95 mm Hg (HR: 5.83;
95% CI: 2.71 to 12.55) compared with <80 mm Hg
(Online Figure 6B). The HR for CAD events was
signiﬁcantly higher in patients with morning
HDBP $90 mm Hg (HR: 3.11; 95% CI: 1.63 to 5.94)
than in those with morning HDBP <75 mm Hg
(Online Figure 6C), and in patients with clinic
DBP $90 to <95 mm Hg (HR: 2.30; 95% CI: 1.07 to
4.92) and $95 mm Hg (HR: 3.01; 95% CI: 1.17 to 7.79)
compared with <80 mm Hg (Online Figure 6D).DISCUSSION
The present analysis of the HONEST study, which
included >20,000 Japanese hypertensive patients,
shows that morning HBP is a strong predictor of
future CAD events, as well as stroke events, and
may be superior to CBP (Central Illustration). The
analysis also shows that there does not appear to be
a J-curve in the relationship between morning HBP
and stroke or CAD events. The relationship between
HBP, compared with CBP, and cardiovascular events
has been investigated in several studies. In the
Ohasama study (6,7), Finn-HOME study (8), and
SHEAF study (12), HBP was found to be superior to
CBP for the prediction of cardiovascular events.
However, in the PAMELA (Pressioni Arteriose
Monitorate e Loro Associazioni) study (11) and a
TABLE 2 Improvement in Goodness-of-Fit to Model for Stroke or CAD by Addition of
CSBP and/or MHSBP*
Likelihood Ratio Chi-Square (p Value)
Stroke Events CAD Events
Vs. Model A Vs. Model B Vs. Model A Vs. Model B
A: confounders only — —
B: confounders þ CSBP 26.38 (<0.001) — 10.81 (<0.05) —
D: confounders þ CSBP
þ MHSBP
45.04 (<0.001) 18.66 (<0.001) 31.87 (<0.001) 21.06 (<0.001)
Vs. Model A Vs. Model C Vs. Model A Vs. Model C
A: confounders only — —
C: confounders þ MHSBP 33.19 (<0.001) — 28.07 (<0.001) —
D: confounders þ MHSBP
þ CSBP
45.04 (<0.001) 11.85 (<0.05) 31.87 (<0.001) 3.80 (0.434)
*Confounders included sex, age, family history of cardiovascular disease, dyslipidemia, diabetes mellitus, chronic
kidney disease, history of cardiovascular disease, and smoking status.
CAD ¼ coronary artery disease; CSBP ¼ clinic systolic blood pressure; MHSBP ¼ morning home systolic blood
pressure.
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1525study by Niiranen et al. (16), HBP was found to be a
useful predictor, but had a predictive ability similar
to CBP. Although information regarding the rela-
tionship between HBP and cardiovascular events
has been accumulating, few studies have investi-
gated the relationship between HBP and CAD
events. In particular, very few studies have inves-
tigated myocardial infarction separately (9,10), and
no signiﬁcant association has been found between
HBP and myocardial infarction because of the small
number of such events.
RELATIONSHIP BETWEEN HSBP AND STROKE
EVENTS. This analysis of data from the HONEST
study has shown that morning and evening HSBP,
like CSBP, are strong predictors for stroke. The
incidence of stroke events was 2.92 per 1,000
patient-years (127 events), similar to that found in
previous studies: HOMED-BP (Multicenter Hyperten-
sion Objective Treatment Based on Measurement
by Electrical Devices Blood Pressure) trial (usual
control, 1.87; tight control, 2.30) (9) and J-HEALTH
(Japan Hypertension Evaluation with Angiotensin II
Antagonist Losartan Therapy) study (2.88 per 1,000
patient-years) (10). In previous studies, the relation-
ship between stroke events and HBP or CBP has
been investigated (7,10,17). In the Ohasama study,
increased HBP, but not CBP, was found to signiﬁcantly
increase the HR for stroke and transient ischemic
attack (7). In contrast, in the J-HEALTH study, stroke
events increased with increases in both CBP and HBP.
As for ABPM, our Jichi Medical University ABPM study
(17) showed that morning SBP, evaluated by ABPM,
has a stronger ability to predict stroke events than
CSBP.
RELATIONSHIP BETWEEN HSBP AND CAD EVENTS.
This analysis shows that morning HBP is a strong
predictor of future CAD events and may be superior to
CBP or evening HBP. The incidence of CAD events
was similar to that for stroke events. The incidence of
CAD events was signiﬁcantly higher in patients with
morning HSBP $145 mm Hg than in those with
morning HSBP <125 mm Hg. However, for CSBP, the
incidence of CAD events was higher only in patients
with CSBP $160 mm Hg compared with <130 mm Hg.
Furthermore, the HR for CAD events was signiﬁcantly
higher in patients with morning HSBP $155 mm Hg,
and it tended to increase from 145 mm Hg. However,
for CSBP, the HR for CAD events increased only in
patients with CSBP $160 mm Hg. The ﬁnding in the
present study that morning HSBP is superior to CSBP
was obtained by analysis using 4 morning HBP mea-
surements (2 measurements over 2 different days) for
each measurement point, whereas there was only 1measurement of CBP. Therefore, there is the possibility
that fewer HBP measurements might not be more
effective than CBP. Although the observed superiority
of morning HBP may be a function of multiple mea-
surements, HBP has an advantage over CBP in terms of
themultiplemeasurements andbeing easy tomeasure.
To examine the signiﬁcance of morning HSBP and
CSBP in CAD risk prediction, we conducted a
goodness-of-ﬁt analysis. The goodness-of-ﬁt of the
model for stroke events was similar between morning
HSBP and CSBP (increment of the likelihood ratio
statistics: 33.19 vs. 26.38), indicating that both are
important factors in the prediction of stroke events.
In contrast, CSBP was signiﬁcantly, but more weakly
associated with CAD events than morning HSBP
(increment of the likelihood ratio statistics: 10.81 vs.
28.07). The goodness-of-ﬁt of the model for CAD
events did not signiﬁcantly improve when CSBP was
entered into the model already including morning
HSBP (increment of likelihood ratio statistics: 3.80;
degrees of freedom: 4; p ¼ 0.434). These results
suggest that morning HSBP is much more important
than CSBP for predicting CAD events. Moreover, the
incidence and HR of CAD events increased signiﬁ-
cantly in patients with evening HSBP >155 mm Hg,
but not in those with evening HSBP 145 to <155
mm Hg. Therefore, morning HSBP may be superior to
evening HSBP in the prediction of CAD events.
Regarding ambulatory BP, the results of the IDACO
study showed that 24-h DBP and isolated diastolic
hypertension could be considered as predictors of
CAD in untreated people <50 years of age (14). Few
reports have investigated the predictive ability of
HBP for CAD events, and the present study is the ﬁrst
to show that morning HSBP may be superior to CSBP
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Morning home blood pressure may
be superior to clinic BP as a predictor of coronary
events and stroke in patients with hypertension.
TRANSLATIONAL OUTLOOK: Randomized
controlled trials are needed to conﬁrm the relation-
ship between morning HBP readings and future
ischemic events and to determine whether therapy
speciﬁcally targeted to lowing morning BP reduces
the frequency of these events.
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1526for the prediction of CAD events. CAD events occur
most frequently in the morning (21), and this phe-
nomenon may be associated with an increase in BP
and BP variability in the morning, resulting from
increased activity of the renin-angiotensin system, as
well as increased platelet function activity and a
thrombotic tendency at this time of the day. There-
fore, morning HBP can be a useful predictor of CAD
events, providing assessment of BP at the time when
CAD events are most likely to occur.
J-CURVE PHENOMENON. The J-curve phenomenon
is the term used to describe the relationship between
BP and cardiovascular risk when a plot of risk against
BP assumes a J shape; this has been a ﬁnding in
several studies. In the INVEST (International Verap-
amil SR–Trandolapril Study), in which patients with
hypertension complicated with CAD were enrolled,
risks for all-cause death and myocardial infarction
increased at DBP <70 to 80 mm Hg (22). In the Systolic
Hypertension in Europe trial, event risk increased at
DBP <70 mm Hg in patients with systolic hyperten-
sion complicated with CAD (23). In the PATE (Practi-
tioner’s Trial on the Efﬁcacy of Antihypertensive
Treatment in the Elderly) Hypertension study, car-
diac events increased at SBP <120 mm Hg, although
the J-curve was not found with stroke events (24). In
the present study, there does not appear to be a
J-curve phenomenon in the relationship between
morning HBP and stroke or CAD events. As for
morning HSBP <125 mm Hg, no conclusion has been
reached because of the small numbers of stroke or
CAD events. However, the results of the subsequent
spline regression analysis showed that there was no
increase in relative risks of stroke and CAD events in
patients with morning HSBP <125 mm Hg.
HOME DBP. In the HONEST study, we also investi-
gated the relationship between morning HDBP or
CDBP and CAD events. Both morning HDBP and CDBP
may underestimate the risk of CAD events com-
pared with morning HSBP or CSBP. No study hasinvestigated the association between HDBP and CAD.
The IDACO ABPM study showed that 24-h DBP and
isolated diastolic hypertension predict CAD in un-
treated people <50 years of age (14).
STUDY LIMITATIONS. The ﬁndings of the present study
are limited by the study design, which was intended
to reﬂect real-world clinical practice; the BP target
was at the discretion of the individual physician,
combination therapy was unrestricted, and there
was no control group. Therefore, this is a trial of
achieved BP.
CONCLUSIONS
Morning HBP is a strong predictor of future CAD
events, as well as stroke events, and may be superior
to CBP in this regard. Furthermore, there does not
appear to be a J-curve in the relationship between
morning HBP and stroke or CAD events.
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